Gastrointestinal Stromal Tumor (GIST)

Adult trials (Ages 18 and older)

Interventional trials

All Mutation Types (KIT, PDGFRA D842V, Wild)

- 2nd Line Only
  - IRB #19262
    A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)

- 3rd or 4th Line
  - IRB #20580
    Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies

KIT and PDGFRA (D842V) Mutations

- At least 1 prior therapy
  - IRB #17155
    A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

PDGFRA D842V Only

- 2nd or 3rd Line
  - IRB #21229
    Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects with Advanced Gastrointestinal Stromal Tumor

EXPANDED ACCESS PROGRAMS:

- IRB# 19992 EAY131 (MATCH)
- IRB# 18084 51609 (DART)

CROSS-DISEASE TRIALS:

http://www.ohsu.edu/research/rda/so/knight.php

24APR2020